Archive · 6 Sep 2025
FDA Tightens Control on GLP-1 Drug Ingredient Imports
The FDA is cracking down on ingredients used in weight loss and diabetes drugs coming into the US.
They're worried that some of these ingredients might be unsafe or fake.
To prevent this, the FDA will now hold shipments at the border if they look suspicious.
Companies importing these ingredients will have to prove their products are safe before they can sell them.
The FDA found problems with many manufacturing sites outside the US.
However, some countries, like Belgium, Canada, China, and India, have sites that meet FDA standards.
FDA is increasing oversight of GLP-1 drug ingredient imports.
Action follows safety concerns regarding adulterated ingredients.
The FDA will detain shipments without inspection.
Importers must provide proof of quality and compliance.
Some manufacturing sites outside the US are non-compliant.
- Who
- US FDA
- What
- Tightening import oversight of GLP-1 drug ingredients
- When
- Announced on September 6, 2025
- Where
- US ports
- Why
- Concerns of adulteration and safety risks
- Agency Action
- FDA tightens import oversight
- Affected Ingredients
- GLP-1 drug ingredients
- Reason for Action
- Concerns about adulteration and safety
- Action Taken
- Detention without physical examination
- Non-Compliant Sites
- 21% of evaluated sites
- Countries Meeting Criteria
- Belgium, Canada, China, India
Sources
Lilly, Novo Sink on FDA List of Foreign GLP-1 Manufacturers
Anti-Obesity Diabetes Drugs Get WHO's Essential Medicine Tag
Anti-Obesity Diabetes Drugs Get WHO's Essential Medicine Tag
Mounjaro and Ozempic get WHO nod, added to essential medicines for diabetes, anti obesity